In November 2019, Kos designed, developed, and implemented the Symbicort® (Budesonide/Formoterol) Pharmacy. AstraZeneca Pty Ltd is pleased to introduce the Program with PharmaPrograms. The primary aim of the Program is to support medication compliance and adherence for both asthma and COPD patients via tailored Quality Use of Medicines (QUM) information.
About Kos Sclavos
This author has yet to write their bio.Meanwhile lets just say that we are proud Kos Sclavos contributed a whooping 21 entries.
Entries by Kos Sclavos
In November 2019, Kos designed, developed, and implemented the Valdoxan Patient Program with Servier Laboratories (Aust) Pty Ltd). Servier has partnered with PharmaPrograms to provide the Program which supports patients prescribed Valdoxan (agomelatine) tablets. This medication is a private prescription-only medicine used to treat depression in adults including to prevent relapse.
In March 2019, Kos designed, developed, and implemented the Amgen Pharmacy Partnership in Osteoporosis INTervention (APPOINT) Program. Recognising the critical role that pharmacy plays in identifying and treating osteoporosis Amgen Australia has joined with PharmaPrograms to create the Program with the aim of supporting pharmacies to reduce osteoporotic fractures.
In June 2018, Kos designed, developed, and implemented the Astellas Urology Patient Program through community pharmacies. The program was supported by Astellas Pharma Australia Pty. Ltd. in partnership with PharmaPrograms. Patients prescribed Betmiga® (mirabegron) and Vesicare® (solifenacin succinate) are able to participate in this Astellas Urology Patient Program.
In April 2018, Kos designed, developed, and implemented the MSD Brenzys® Pharmacy Program which provides support to patients who have been dispensed Brenzys® (etanercept). Participating patients are eligible to be enrolled in the MSD Harmony™. It is a biosimilar to the reference biological medicine Enbrel© (etanercept).
In April 2019, Kos designed, developed, and implemented the Flomaxtra® Patient Program through community pharmacies. Flomaxtra® (tamsulosin hydrochloride) tablets 0.4mg is an authority Repatriation Pharmaceutical Benefit and a private Prescription-Only Medicine for other patients. It is used to treat men who have symptoms associated with Benign Prostatic Hyperplasia (also known as BPH).
In 2016 Kos designed, developed, and implemented the Saxenda® Pharmacy Program in over 2,700 pharmacies. Saxenda® is currently a non-PBS funded medication from Novo Nordisk Australia Pty Ltd. The program facilitates pharmacist engagement with patients to help ensure their quality use of medicines
In 2015 Kos designed, developed, and implemented the Brintellix® Patient Program in over 2,500 pharmacies. Brintellix® is currently a non-PBS funded medication from Lundbeck Australia Pty Ltd. The program facilitates pharmacist engagement with patients to help ensure their quality use of medicines.
In 2018 Kos designed, developed, and implemented the Nurofen Plus® Patient Program. The Program will continue to make Nurofen Plus® Tablets available to Australian patients as a Prescription Only under a Quality Use of Medicines (QUM) framework.
In March 2018, Kos designed, developed, and implemented the Emerge Health Patient Program. Emerge Health Pty Ltd partnered with PharmaPrograms to facilitate the streamlined dispensing of Sativex® Oromucosal Spray, nabiximols 80 mg/mL pump actuated metered dose aerosol (ARTG ID 181978) through community pharmacies.